[Promotor hypermethylation of E-cadherin, p16 and estrogen receptor in prostate carcinoma].
To investigate promotor hypermethylation of the CpG islands of E-Cadherin, p16 and estrogen receptor (ER) in prostate carcinoma and explore whether such methylation might play a role in the tumorigenesis and malignant progression of prostate carcinoma and their significance in the diagnosis, prognosis and treatment. Thirteen specimens of benign prostatic hypertrophy (BPH), 10 specimens of high grade prostate intraepithelial neoplasia (HGPIN) and 20 specimens of prostate carcinoma (with follow-up records) were collected from the patients who underwent radical prostatectomy or transurethral resection. Methylation-specific PCR (MSP) was used to detect the promoter hypermethylation of E-Cadherin, p16 and ER genes. Hypermethylation percentages in prostate carcinoma were: E-Cadherin, 30%; p16, 25%; and ER, 65%. Almost all nonmalignant tissues (BPH and HG-PIN) lacked methylation of any genes. Detecting promotor hypermethylation of E-Cadherin, p16 and ER may be helpful to differentiate nonmalignant lesions from prostate carcinoma.